Trump locks Medicaid drug savings into every state

President Donald Trump stood in the Oval Office on Friday, Sept. 18, 2026, flanked by Health and Human Services Secretary Robert F. Kennedy Jr., Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and governors including Larry Rhoden, Sarah Huckabee Sanders and Tate Reeves, and announced that every Medicaid program in the country was in. All 50 states, the District of Columbia and Puerto Rico would join the Medicaid GENEROUS model linking selected drug prices to those paid in other developed countries.

That single fact resets the ledger for a program that already serves about 70 million Americans. The White House Council of Economic Advisers projects $27.6 billion in state savings and $36.6 billion in federal savings over 10 years, $64.3 billion in total, figures some reports round to $64 billion or $65 billion. Trump told reporters the announcement "should win us the midterms." He added, "Every state will have the ability to use those extra billions of dollars to invest in other healthcare improvements or something else."

Most-favored-nation pricing, as the administration has defined it, means participating manufacturers pay rebates so Medicaid’s net price on selected brand-name medicines does not exceed a benchmark tied to prices in comparable developed countries. The administration says it has signed agreements with more than two dozen pharmaceutical manufacturers, 26 in all, including Pfizer, Eli Lilly and Novo Nordisk, covering 90 percent of the branded U.S. market. Some drugs could be discounted by as much as 90 percent. The White House fact sheet projects broader most-favored-nation deals at $600 billion over a decade, up from an earlier May estimate of $529 billion over 10 years.

Those numbers matter first to taxpayers and state budgets. Medicaid is jointly financed. Lower net acquisition costs free money at both levels of government. Trump’s point was straightforward: the savings are real dollars states can redirect. Medicaid beneficiaries already pay nominal copayments of a few dollars under existing law, and the program already receives mandatory discounts. The immediate fiscal relief therefore lands on the public books rather than as a dramatic new cut at the pharmacy counter for every enrollee. For governors watching crowded budgets, that distinction is the practical one.

The same 26 companies have committed about $170 billion to U.S. manufacturing and research and development and are stocking the Strategic Active Pharmaceutical Ingredients Reserve. The administration presents that capital as the other half of the bargain: lower prices here, production and supply security at home. Prescription drug prices, per the administration, have recorded their steepest annual decline since 1963. TrumpRx, the platform already operating alongside these deals, has delivered more than $700 million in savings and covers more than 1,000 branded and generic medicines. GLP-1 drugs that once cost $1,000 a month now start as low as $149; eligible Medicare seniors pay $50 a month, with more than 500,000 seniors already saving $216 million.

Steve Ubl answered the policy in blunt terms. He called it "importing foreign prices from socialist countries" and said the approach "would mean less treatments and cures and would jeopardize the hundreds of billions our member companies are planning to invest in America." The administration’s counter sits in the commitments already on paper: the $170 billion pledged to domestic manufacturing and R&D, the reserve of active ingredients, and the voluntary agreements covering the large majority of the branded market. The record does not show Ubl withdrawing those investment figures; it shows the companies signing both the pricing arrangements and the domestic build-out.

Transparency is the second line of objection. Kathy Hempstead said Trump wants Congress to codify the arrangements but that the demand is hard to meet in practice. "He is saying Congress should codify all of his MFN arrangements. But it's kind of unreasonable because it's not clear what Congress would actually do. No one knows what is in these deals," she said. She also flagged uncertainty about whether the price cuts would last beyond the current administration. JD Hayworth called Friday’s step "meaningful progress, but that progress remains incomplete," noting that millions of Americans outside government programs still want lower prices. The agreements themselves have not been released in full, so independent analysts cannot yet recalculate the $64.3 billion Medicaid figure or the wider $600 billion claim from primary contract terms.

Kush Desai answered the disclosure critique directly. He pointed to drug deals negotiated in the prior administration under the Inflation Reduction Act that likewise withheld commercially sensitive information, and said experts "now poking holes at the Trump administration for also not wanting to disclose commercially sensitive information should be regarded as either an idiot or partisan hack." The record carries no public release of the full rebate schedules, the complete drug list, or the precise foreign-price formula used for each medicine. It does carry the administration’s stated totals, the roster of more than two dozen manufacturers, the coverage claim of 90 percent of the branded market, and the governors who stood in the Oval Office as their states joined.

For limited government and the taxpayer, the sequence is the argument. Washington did not invent a new entitlement. It used executive agreements and a CMS model to drive net prices on selected high-cost drugs toward an international benchmark, then folded every state Medicaid program into the result. States keep the fiscal dividend. Patients on Medicaid keep their existing nominal copays while the programs that cover them spend less. Seniors already seeing TrumpRx discounts on GLP-1 drugs and other medicines have a concrete ledger of hundreds of millions saved. Manufacturers that want access keep investing in American plants and the strategic ingredients stockpile rather than leaving the supply chain dependent on foreign production alone.

The other side’s best case, stated in its own words, is that foreign reference pricing can shrink the returns that fund future treatments and that secret deal terms make congressional codification and outside verification difficult. The facts the administration puts forward in reply are the signed company list, the $170 billion manufacturing and R&D commitment, the reserve, the measured price decline since 1963, the TrumpRx savings already booked, and the Council of Economic Advisers’ decade-long Medicaid projection split between state and federal ledgers. No Democrat on the public record compiled for this announcement has supplied an alternative scored savings figure; the governor’s offices represented in the Oval Office appeared to accept the model by standing with the president as it went nationwide.

Cost-of-living pressure sits at the center of the November midterms. Trump’s bet, spoken aloud in the Oval Office, is that locking most-favored-nation pricing into every Medicaid program is the kind of tangible result voters can test against their own state budgets and pharmacy realities. The GENEROUS model is now the baseline in all 50 states, the District of Columbia and Puerto Rico. The next decision belongs to voters in November, and to any Congress asked to write the arrangements into statute without yet seeing every page of the underlying contracts.